Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 7/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CMA1 | P23946 | 5/20 | 0.60 |
| ▸ | REN | P00797 | 3/20 | 0.56 |
| ▸ | ACE2 | Q9BYF1 | 5/20 | 0.55 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22961962 | 0.94 | ACE (0.72) | ACECMA1ACE2F2PRSS1 | |
| SCHEMBL5900839 | 0.90 | ACE (0.77) | ACECMA1ACE2F2PRSS1 | |
| SCHEMBL22409423 | 0.90 | ACE (0.77) | ACECMA1ACE2F2PRSS1 | |
| SCHEMBL3692085 | 0.90 | ACE (0.77) | ACECMA1ACE2F2PRSS1 | |
| SCHEMBL5900836 | 0.90 | ACE (0.77) | ACECMA1ACE2F2PRSS1 | |
| SCHEMBL3692081 | 0.90 | ACE (0.77) | ACECMA1ACE2F2PRSS1 | |
| SCHEMBL8378100 | 0.90 | ACE (0.77) | ACECMA1ACE2F2PRSS1 | |
| SCHEMBL20173777 | 0.89 | ACE (0.65) | ACERENACE2 | |
| SCHEMBL22962169 | 0.88 | ACE (0.67) | ACECMA1ACE2F2PRSS1 | |
| SCHEMBL23832913 | 0.87 | ACE (0.55) | ACEMAPK1CMA1RENACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10889543-B2 | Fine-tune modulators of neuronal excitability for neuropsychiatric disorders | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190270705-A1 | FINE-TUNE MODULATORS OF NEURONAL EXCITABILITY FOR NEUROPSYCHIATRIC DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2019-09-05 | — | — | US | disclosed |
| WO-2018094335-A1 | FINE-TUNE MODULATORS OF NEURONAL EXCITABILITY FOR NEUROPSYCHIATRIC DISORDERS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889543-B2 | Fine-tune modulators of neuronal excitability for neuropsychiatric disorders | CACNG6, KCNN3, SCN1B | ACE 3992/4885MAPK1 3059/4885CMA1 4703/4885 |
| US-20190270705-A1 | FINE-TUNE MODULATORS OF NEURONAL EXCITABILITY FOR NEUROPSYCHIATRIC DISORDERS | CACNG6, KCNN3, SCN1B | ACE 3992/4885MAPK1 3059/4885CMA1 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.